Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the most prevalent cause of dementia with ageing. The etiology of this illness is rather complex and not completely known but deposits of aberrant β- amyloid protein, as well as τ-protein hyperphosphorylation, oxidative stress, dyshomeostasis of biometals and low levels of acetylcholine (ACh) seem to play a significant role. Such complex etiology of AD has encouraged active research in the development of multi-target drugs with two or more complementary biological activities, since they may represent an important advance in the treatment of this disease. Dual inhibitors combining anti-acetyl cholinesterase (AChE) and antimonoamine oxidase (MAO) activities in one molecular entity have been recently reported. Inhibition of AChE increases neurotransmission at cholinergic synapses and reduce temporally the cognitive deficit. AChE also participates in other functions related to neuronal development, differentiation, adhesion and β-amyloid protein processing. In addition MAOB inhibition retards further deterioration of cognitive functions. In this review relevant aspects about structure, mechanism and pharmacological effects of these dual inhibitors are reported.
Keywords: Neurodegenerative disorders, Alzheimer disease, multi-target drugs, cholinesterase inhibitors, monoamine oxidase inhibitors.
Current Topics in Medicinal Chemistry
Title:Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease
Volume: 13 Issue: 14
Author(s): Matilde Yanez and Dolores Vina
Affiliation:
Keywords: Neurodegenerative disorders, Alzheimer disease, multi-target drugs, cholinesterase inhibitors, monoamine oxidase inhibitors.
Abstract: Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the most prevalent cause of dementia with ageing. The etiology of this illness is rather complex and not completely known but deposits of aberrant β- amyloid protein, as well as τ-protein hyperphosphorylation, oxidative stress, dyshomeostasis of biometals and low levels of acetylcholine (ACh) seem to play a significant role. Such complex etiology of AD has encouraged active research in the development of multi-target drugs with two or more complementary biological activities, since they may represent an important advance in the treatment of this disease. Dual inhibitors combining anti-acetyl cholinesterase (AChE) and antimonoamine oxidase (MAO) activities in one molecular entity have been recently reported. Inhibition of AChE increases neurotransmission at cholinergic synapses and reduce temporally the cognitive deficit. AChE also participates in other functions related to neuronal development, differentiation, adhesion and β-amyloid protein processing. In addition MAOB inhibition retards further deterioration of cognitive functions. In this review relevant aspects about structure, mechanism and pharmacological effects of these dual inhibitors are reported.
Export Options
About this article
Cite this article as:
Yanez Matilde and Vina Dolores, Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease, Current Topics in Medicinal Chemistry 2013; 13 (14) . https://dx.doi.org/10.2174/15680266113139990120
DOI https://dx.doi.org/10.2174/15680266113139990120 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Applying Epigenetics to Alzheimer’s Disease via the Latent Early–life Associated Regulation (LEARn) Model
Current Alzheimer Research Harnessing the Capacity of Cell-Penetrating Peptides for Drug Delivery to the Central Nervous System
Current Pharmaceutical Biotechnology Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies
Current Neuropharmacology Identification of Inflammatory, Metabolic, and Cell Survival Pathways Contributing to Cerebral Small Vessel Disease by Postmortem Gene Expression Microarray
Current Neurovascular Research Models of Parkinson’s Disease with Special Emphasis on Drosophila melanogaster
CNS & Neurological Disorders - Drug Targets Structural Characterization of Amyloid β17-42 Dimer by Potential of Mean Force Analysis: Insights from Molecular Dynamics Simulations
Protein & Peptide Letters Effects of Novel Monoamine Oxidases and Cholinesterases Targeting Compounds on Brain Neurotransmitters and Behavior in Rat Model of Vascular Dementia
Current Pharmaceutical Design Screening of Natural Compounds Against SOD1 as a Therapeutic Target for Amyotrophic Lateral Sclerosis
Letters in Drug Design & Discovery Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal The Role of miR-124 in Drosophila Alzheimer's Disease Model by Targeting Delta in Notch Signaling Pathway
Current Molecular Medicine Antimicrobial Impacts of Essential Oils on Food Borne-Pathogens
Recent Patents on Food, Nutrition & Agriculture Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo
CNS & Neurological Disorders - Drug Targets Intracompartmental Delivery of CNTF as Therapy for Huntingtons Disease and Retinitis Pigmentosa
Current Gene Therapy The Protective Effects of Jatrorrhizine on β-Amyloid (25-35)-Induced Neurotoxicity in Rat Cortical Neurons
CNS & Neurological Disorders - Drug Targets Clinical Characteristics and Possible Drug Targets in Autosomal Dominant Spinocerebellar Ataxias
CNS & Neurological Disorders - Drug Targets SiRNA Mediated Gene Silencing: Hurdles, Strategies and Applications
Pharmaceutical Nanotechnology Nutraceuticals: A Comparative Analysis of Regulatory Framework in Different Countries of the World
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetic Variants and Oxidative Stress in Alzheimer’s Disease
Current Alzheimer Research Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Proteomic Approaches Contributing to the Understanding of Neurodegenerative Diseases: Focus on Alzheimers Disease
Current Proteomics